Jane Huang - Jul 4, 2023 Form 4 Insider Report for Prelude Therapeutics Inc (PRLD)

Role: President, CMO
Signature: /s/ Laurent Chardonnet, Attorney-in-Fact
Stock symbol: PRLD
Transactions as of: Jul 4, 2023
Transactions value $: -$15,075
Form type: 4
Date filed: 7/6/2023, 04:35 PM
Previous filing: Jun 8, 2023
Next filing: Oct 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRLD	Common Stock	Options Exercise		+9.38K	+38.71%		33.6K	Jul 4, 2023	Direct	F1
transaction	PRLD	Common Stock	Tax liability	-$15.1K	-3.24K	-9.65%	$4.65	30.4K	Jul 4, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PRLD	Restricted Stock Unit	Options Exercise	$0	-9.38K	-8.33%	$0.00	103K	Jul 4, 2023	Common Stock	9.38K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2	Represents shares withheld by the Issuer to satisfy the tax withholding obligation in connection with the vesting of RSUs.
F3	The RSUs were granted on May 2, 2022 and vest according to the reporting person's employment agreement. The RSUs vested as to 1/4 of the total shares on April 4, 2023, and 1/16 of the remaining shares shall vest quarterly thereafter until fully vested, subject to the continued service of the Reporting Person to the Issuer through each vesting date.